Overview:

Summary

Global Markets Direct’s, 'Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, Q2 2011', provides an overview of the Acquired (Autoimmune) Hemolytic Anemia therapeutic pipeline. This report provides information on the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia. 'Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acquired (Autoimmune) Hemolytic Anemia.
- A review of the Acquired (Autoimmune) Hemolytic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acquired (Autoimmune) Hemolytic Anemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acquired (Autoimmune) Hemolytic Anemia pipeline depth and focus of Acquired (Autoimmune) Hemolytic Anemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acquired (Autoimmune) Hemolytic Anemia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia 7
Acquired (Autoimmune) Hemolytic Anemia Therapeutics under Development by Companies 9
Acquired (Autoimmune) Hemolytic Anemia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Products under Development by Companies 15
Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Acquired (Autoimmune) Hemolytic Anemia Therapeutics Development 17
Accentia Biopharmaceuticals, Inc. 17
Acquired (Autoimmune) Hemolytic Anemia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Late Stage Drug Profiles 24
Revimmune - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Alemtuzumab + Rituximab - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Sirolimus - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Cyclophosphamide + Filgrastim - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Mabthera - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Prednisolone + Mabthera - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Rituximab + Prednisone - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Acquired (Autoimmune) Hemolytic Anemia Therapeutics – Drug Profile Updates 32
Acquired (Autoimmune) Hemolytic Anemia - Featured News 33
May 23, 2011: Researchers To Present Nine Studies On Alexion's Soliris In Patients With PNH And aHUS At EHA Congress 33
Feb 28, 2007: Accentia Biopharmaceuticals Acquires Worldwide Exclusive License To Revimmune 34
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 38
Contact Us 38
Disclaimer 38"

List of Tables
Number of Products Under Development for Acquired (Autoimmune) Hemolytic Anemia, Q2 2011 7
Products under Development for Acquired (Autoimmune) Hemolytic Anemia – Comparative Analysis, Q2 2011 8
Number of Products under Development by Companies, Q2 2011 9
Number of Products under Investigation by Universities/Institutes, Q2 2011 11
Comparative Analysis by Late Stage Development, Q2 2011 12
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 13
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011 14
Products under Development by Companies, Q2 2011 15
Products under Investigation by Universities/Institutes, Q2 2011 16
Accentia Biopharmaceuticals, Inc., 2011 17
Assessment by Monotherapy Products, Q2 2011 18
Assessment by Combination Products 19
Assessment by Stage and Route of Administration, Q2 2011 21
Assessment by Molecule Type, Q2 2011 23
Acquired (Autoimmune) Hemolytic Anemia Therapeutics – Drug Profile Updates 32"

List of Figures
Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, Q2 2011 7
Products under Development for Acquired (Autoimmune) Hemolytic Anemia – Comparative Analysis, Q2 2011 8
Products under Development by Companies, Q2 2011 9
Products under Investigation by  Universities/Institutes, Q2 2011 10
Late Stage Products, Q2 2011 12
Mid Clinical Stage Products, Q2 2011 13
Pre-Clinical Stage Products, Q2 2011 14
Assessment by Monotherapy Products, Q2 2011 18
Assessment by Combination Products, Q2 2011 19
Assessment by Route of Administration, Q2 2011 20
Assessment by Stage and Route of Administration, Q2 2011 21
Assessment by Molecule Type, Q2 2011 22
Assessment by Stage and Molecule Type, Q2 2011 23